The impact of obesity on the risk of developing, activity and treatment outcomes of autoimmune rheumatic diseases
DOI:
https://doi.org/10.12775/QS.2026.56.72004Keywords
obesity, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, axial spondyloarthritisAbstract
Background:
Obesity is becoming a new epidemic. It is the cause of numerous serious medical complications. Obesity is associated with chronic low-grade inflammation, oxidative stress, and increased expression of pro-inflammatory cytokines and adipokines. Autoimmune rheumatic diseases are driven by similar mediators and immunological dysregulations, which are disturbed in obesity. It suggests potential associations between obesity and these diseases.
Aim:
The aim of this review is to examine evidence on how obesity affects the risk of developing common rheumatic diseases, the activity/severity of these diseases, and the outcomes of treatment.
Material and methods:
A literature search was conducted in the PubMed database up to February 2026 using the following terms: “obesity” and “BMI”, in combination with disease-specific keywords. Only articles published in English or with an available English abstract were included. Only studies on humans were included. Meta-analyses and cohort studies were prioritised. Additionally, two relevant conference abstracts [23, 27] that were not indexed as full records in PubMed were identified via manual screening of reference lists and included in the review. The literature selection process and the flow of information at each stage of the review were presented in accordance with the PRISMA guidelines.
Conclusions:
Obesity increases the risk of development of rheumatoid arthritis and psoriasis and there is some evidence of common genetic backgrounds. Childhood obesity increases the risk of developing systemic lupus erythematosus, whereas the association with adult obesity is less consistent. There are positive correlations between body mass index and disease activity in rheumatoid arthritis, psoriasis and ankylosing spondylitis, as well as with certain clinical manifestations, including lupus nephritis and psoriatic arthritis. Obesity significantly reduces the likelihood of good treatment outcomes with anti-TNF agents.
References
1. Eurostat. Overweight and obesity – BMI statistics [Internet]. Luxembourg: Eurostat; 2024 [cited 2026 Feb 27]. Available from: https://doi.org/10.2908/ILC_HCH10 Also available from: https://ec.europa.eu/eurostat/statistics-explained/SEPDF/cache/12376.pdf and https://ec.europa.eu/eurostat/databrowser/view/ilc_hch10/default/table?lang=en
2. GBD 2021 Adult BMI Collaborators. Global, regional, and national prevalence of adult overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet. 2025;405(10481):813–838. Available from: https://doi.org/10.1016/S0140-6736(25)00355-1
3. Global BMI Mortality Collaboration, Di Angelantonio E, Bhupathiraju SN, Wormser D, et al. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016;388(10046):776–786. Available from: https://doi.org/10.1016/S0140-6736(16)30175-1
4. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023–2038. Available from: https://doi.org/10.1016/S0140-6736(16)30173-8 Erratum in: Lancet. 2016;388(10055):1984. Available from: https://doi.org/10.1016/S0140-6736(16)30794-2
5. Restivo V, Candiloro S, Daidone M, Norrito R, Cataldi M, Minutolo G, et al. Systematic review and meta-analysis of cardiovascular risk in rheumatological disease: symptomatic and non-symptomatic events in rheumatoid arthritis and systemic lupus erythematosus. Autoimmun Rev. 2022;21(1):102925. Available from: https://doi.org/10.1016/j.autrev.2021.102925
6. GBD 2021 Rheumatoid Arthritis Collaborators. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5(10):e594–e610. Available from: https://doi.org/10.1016/S2665-9913(23)00211-4
7. Ohno T, Aune D, Heath AK. Adiposity and the risk of rheumatoid arthritis: a systematic review and meta-analysis of cohort studies. Sci Rep. 2020;10(1):16006. Available from: https://doi.org/10.1038/s41598-020-71676-6
8. Flores-Alvarado DE, Esquivel-Valerio JA, Vega-Morales D, Garza-Cisneros AN, Balderas-Palacios MA, Galarza-Delgado DA, et al. Impact of obesity and overweight on C-reactive protein concentrations and disease activity in rheumatoid arthritis: a systematic review and meta-analysis. Int J Rheum Dis. 2023;26(12):2498–2508. Available from: https://doi.org/10.1111/1756-185X.14948
9. Ajeganova S, Forslind K, Hafström I. The equivocal opposite effects of lower and higher body mass index at diagnosis on radiographic joint damage progression in early rheumatoid arthritis: an inception cohort study over 15 years. RMD Open. 2025;11(3):e005784. Available from: https://doi.org/10.1136/rmdopen-2025-005784
10. Vidal C, Barnetche T, Morel J, Combe B, Daïen C. Association of body mass index categories with disease activity and radiographic joint damage in rheumatoid arthritis: a systematic review and meta-analysis. J Rheumatol. 2015;42(12):2261–2269. Available from: https://doi.org/10.3899/jrheum.150224
11. Shan J, Zhang J. Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: a systematic review and meta-analysis. Joint Bone Spine. 2019;86(2):173–183. Available from: https://doi.org/10.1016/j.jbspin.2018.03.007
12. Tidblad L, Öberg Sysojev A, Delcoigne B, Klareskog L, Alfredsson L, Askling J, et al. In early rheumatoid arthritis, comorbidities do not explain the increased risk of failure to reach remission in patients with obesity. RMD Open. 2025;11(2):e005430. Available from: https://doi.org/10.1136/rmdopen-2025-005430
13. Vasileiadis GK, Zhang Y, Fatima T, van Vollenhoven R, Lampa J, Gudbjornsson B, et al. Circulating adipokines and response to treatment in patients with early rheumatoid arthritis. ACR Open Rheumatol. 2025;7(1):e11756. Available from: https://doi.org/10.1002/acr2.11756
14. Liu S, Chen S, Huang Y, Man Q, Yang Y, Wen J, et al. Association of weight-adjusted waist index with all-cause and cardiovascular disease mortality among rheumatoid arthritis population: a cohort study from the NHANES 1999–2018. Lipids Health Dis. 2025;24(1):223. Available from: https://doi.org/10.1186/s12944-025-02594-7
15. Kiriakidou M, Ching CL. Systemic lupus erythematosus. Ann Intern Med. 2020;172(11):ITC81–ITC96. Available from: https://doi.org/10.7326/AITC202006020
16. Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. Ann Rheum Dis. 2023;82(3):351–356. Available from: https://doi.org/10.1136/ard-2022-223035
17. Thomas PE, Jensen BW, Sørensen KK, Jacobsen S, Aarestrup J, Baker JL. Early life body size, growth and risks of systemic lupus erythematosus: a large Danish observational cohort study. Semin Arthritis Rheum. 2020;50(6):1507–1512. Available from: https://doi.org/10.1016/j.semarthrit.2020.01.011
18. Tedeschi SK, Barbhaiya M, Malspeis S, Lu B, Sparks JA, Karlson EW, et al. Obesity and the risk of systemic lupus erythematosus among women in the Nurses' Health Studies. Semin Arthritis Rheum. 2017;47(3):376–383. Available from: https://doi.org/10.1016/j.semarthrit.2017.05.011
19. Cozier YC, Barbhaiya M, Castro-Webb N, Conte C, Tedeschi S, Leatherwood C, et al. A prospective study of obesity and risk of systemic lupus erythematosus among Black women. Semin Arthritis Rheum. 2019;48(6):1030–1034. Available from: https://doi.org/10.1016/j.semarthrit.2018.10.004
20. Gomez A, Hani Butrus F, Johansson P, Åkerström E, Soukka S, Emamikia S, et al. Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus. Rheumatology (Oxford). 2021;60(3):1260–1272. Available from: https://doi.org/10.1093/rheumatology/keaa453
21. Kang JH, Xu H, Choi SE, Park DJ, Lee JK, Kwok SK, et al. Obesity increases the incidence of new-onset lupus nephritis and organ damage during follow-up in patients with systemic lupus erythematosus. Lupus. 2020;29(6):578–586. Available from: https://doi.org/10.1177/0961203320913616
22. Cuervo, F., Enfrein, A., Anders, H. J., Houssiau, F. A., & Tamirou, F. (2025). Obesity is an independent poor prognostic factor in lupus nephritis. Lupus, 34(12), 1292–1297. Available from: https://doi.org/10.1177/09612033251375856
23. Stojan G, Timlin H, Fang H, Magder LS, Petri M. Association of body weight with cardiovascular events in systemic lupus erythematosus. Arthritis Rheum. 2012;64(Suppl 10):S228. Presented at: ACR/ARHP Annual Meeting; 2012 Oct 26–31; Washington, DC, USA.
24. Pedrosa T, Kupa LVK, Pasoto SG, Aikawa NE, Borba EF, Duarte NJ, et al. The influence of obesity on hydroxychloroquine blood levels in lupus nephritis patients. Lupus. 2021;30(4):554–559. Available from: https://doi.org/10.1177/0961203320985214
25. Aeamsaard N, Chaiamnuay S, Narongroeknawin P, Asavatanabodee P, Pakchotanon R. The association between serum leptin levels, body mass index, and disease activity in women with systemic lupus erythematosus. Medicine (Baltimore). 2025;104(31):e43646. Available from: https://doi.org/10.1097/MD.0000000000043646
26. Li, H., Du, X., Lv, X., Hao, Z., & He, L. (2025). Correlation between body mass index and disease activity in patients with systemic lupus erythematosus from China. Advances in rheumatology (London, England), 66(1), 3. Available from: https://doi.org/10.1186/s42358-025-00502-2
27. Stojan G, Li J, Petri M. Body mass index at time of diagnosis is predictive of future disease activity in SLE. Arthritis Rheumatol. 2019;71(Suppl 10):694. Presented at: ACR/ARP Annual Meeting; 2019 Nov 8–13; Atlanta, GA, USA.
28. Teruya H, Shoda H, Itamiya T, Tsuchida Y, Okamura T, Fujio K. Body weight in systemic lupus erythematosus is associated with disease activity and the adaptive immune system, independent of type I IFN. Front Immunol. 2025;16:1503559. Available from: https://doi.org/10.3389/fimmu.2025.1503559
29. Garg S, Chewning B, Hutson P, Astor BC, Bartels CM. Reference range of hydroxychloroquine blood levels that can reduce odds of active lupus and prevent flares. Arthritis Care Res (Hoboken). 2024;76(2):241–250. Available from: https://doi.org/10.1002/acr.25228
30. Nishimura S, Manabe I, Takaki S, Nagasaki M, Otsu M, Yamashita H, et al. Adipose natural regulatory B cells negatively control adipose tissue inflammation. Cell Metab. 2013;18(5):759–766. Available from: https://doi.org/10.1016/j.cmet.2013.09.017
31. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301–1315. Available from: https://doi.org/10.1016/S0140-6736(20)32549-6
32. Garshick MS, Ward NL, Krueger JG, Berger JS. Cardiovascular risk in patients with psoriasis: JACC review topic of the week. J Am Coll Cardiol. 2021;77(13):1670–1680. Available from: https://doi.org/10.1016/j.jacc.2021.02.009
33. Damiani G, Bragazzi NL, Karimkhani Aksut C, Wu D, Alicandro G, McGonagle D, et al. The global, regional, and national burden of psoriasis: results and insights from the Global Burden of Disease 2019 Study. Front Med (Lausanne). 2021;8:743180. Available from: https://doi.org/10.3389/fmed.2021.743180
34. Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590. Available from: https://doi.org/10.1136/bmj.m1590
35. Kang Z, Zhang X, Du Y, Dai SM. Global and regional epidemiology of psoriatic arthritis in patients with psoriasis: a comprehensive systematic analysis and modelling study. J Autoimmun. 2024;145:103202. Available from: https://doi.org/10.1016/j.jaut.2024.103202
36. Wang J, Yu Y, Liu L, Wang C, Sun X, Zhou Y, et al. Global prevalence of obesity in patients with psoriasis: an analysis in the past two decades. Autoimmun Rev. 2024;23(6):103577. Available from: https://doi.org/10.1016/j.autrev.2024.103577
37. Wu Y, Huang M, Chen X, Wu J, Li L, Wei J, et al. A genome-wide cross-trait analysis identifies shared loci and causal relationships of obesity and lipidemic traits with psoriasis. Front Immunol. 2024;15:1328297. Available from: https://doi.org/10.3389/fimmu.2024.1328297
38. Antonatos C, Georgakilas GK, Evangelou E, Vasilopoulos Y. Transcriptomic meta-analysis characterizes molecular commonalities between psoriasis and obesity. Genes Immun. 2024;25(3):179–187. Available from: https://doi.org/10.1038/s41435-024-00271-w
39. Tang B, Shi H, Alfredsson L, Klareskog L, Padyukov L, Jiang X. Obesity-related traits and the development of rheumatoid arthritis: evidence from genetic data. Arthritis Rheumatol. 2021;73(2):203–211. Available from: https://doi.org/10.1002/art.41517
40. Belli R, Dattolo A, Sampogna F, Gubinelli E, Lulli D, Moretta G, et al. Leptin: a gender- and obesity-related marker predictive of metabolic comorbidities and therapeutic response to anti-IL-23 biologic drugs in psoriatic patients. Front Immunol. 2025;16:1607312. Available from: https://doi.org/10.3389/fimmu.2025.1607312
41. Aune D, Snekvik I, Schlesinger S, Norat T, Riboli E, Vatten LJ. Body mass index, abdominal fatness, weight gain and the risk of psoriasis: a systematic review and dose-response meta-analysis of prospective studies. Eur J Epidemiol. 2018;33(12):1163-1178. Available from: https://doi.org/10.1007/s10654-018-0366-z
42. Wang H, Hou S, Kang X, et al. BMI matters: understanding the link between weight and severe psoriasis. Sci Rep. 2025;15:11158. Available from: https://doi.org/10.1038/s41598-025-94505-0
43. Xie W, Huang H, Deng X, Gao D, Zhang Z. Modifiable lifestyle and environmental factors associated with onset of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2021;84(3):701-711. Available from: https://doi.org/10.1016/j.jaad.2020.08.060
44. Singh S, Facciorusso A, Singh AG, Vande Casteele N, Zarrinpar A, Prokop LJ, et al. Obesity and response to anti-tumor necrosis factor-α agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis. PLoS One. 2018;13(5):e0195123. Available from: https://doi.org/10.1371/journal.pone.0195123
45. Lupoli R, Pizzicato P, Scalera A, Ambrosino P, Amato M, Peluso R, et al. Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis. Arthritis Res Ther. 2016;18(1):297. Available from: https://doi.org/10.1186/s13075-016-1194-8
46. Vallejo-Yagüe E, Burkard T, Micheroli R, Burden AM. Minimal disease activity and remission in patients with psoriatic arthritis with elevated body mass index: an observational cohort study in the Swiss Clinical Quality Management cohort. BMJ Open. 2022;12(9):e061474. Available from: https://doi.org/10.1136/bmjopen-2022-061474
47. Vata D, Tarcau BM, Popescu IA, Halip IA, Patrascu AI, Gheuca Solovastru DF, et al. Update on obesity in psoriasis patients. Life (Basel). 2023;13(10):1947. Available from: https://doi.org/10.3390/life13101947
48. Eder L, Thavaneswaran A, Chandran V, Cook RJ, Gladman DD. Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. Ann Rheum Dis. 2015;74(5):813-817. Available from: https://doi.org/10.1136/annrheumdis-2013-204448
49. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2(12):e54. Available from: https://doi.org/10.1038/nutd.2012.26
50. Kisielnicka A, Sobalska-Kwapis M, Purzycka-Bohdan D, Nedoszytko B, Zabłotna M, Seweryn M, et al. The analysis of a genome-wide association study (GWAS) of overweight and obesity in psoriasis. Int J Mol Sci. 2022;23(13):7396. Available from: https://doi.org/10.3390/ijms23137396
51. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23(R1):R89-R98. Available from: https://doi.org/10.1093/hmg/ddu328
52. Zafiriou E, Daponte AI, Siokas V, Tsigalou C, Dardiotis E, Bogdanos DP. Depression and obesity in patients with psoriasis and psoriatic arthritis: is IL-17-mediated immune dysregulation the connecting link? Front Immunol. 2021;12:699848. Available from: https://doi.org/10.3389/fimmu.2021.699848
53. Siebert S, Sattar N, Ferguson LD. Weighing in on obesity and psoriatic arthritis - time to move beyond association to robust randomised trials. Joint Bone Spine. 2025;92(5):105904. Available from: https://doi.org/10.1016/j.jbspin.2025.105904
54. Wu MY, Yu CL, Yang SJ, Chi CC. Change in body weight and body mass index in psoriasis patients receiving biologics: a systematic review and network meta-analysis. J Am Acad Dermatol. 2020;82(1):101-109. Available from: https://doi.org/10.1016/j.jaad.2019.07.103
55. Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clin Dermatol. 2018;36(1):21-28. Available from: https://doi.org/10.1016/j.clindermatol.2017.09.005
56. Mehta S, Yang M, Dimitropoulos L, Thib S, Koppikar S, Cook RJ, et al. Association between glucose intolerance and psoriatic arthritis features. RMD Open. 2025;11(2):e005709. Available from: https://doi.org/10.1136/rmdopen-2025-005709
57. Zhao SS, Bowes J, Barton A, Davey Smith G, Richardson T. Separating the effects of childhood and adult body size on inflammatory arthritis: a Mendelian randomisation study. RMD Open. 2022;8(2):e002321. Available from: https://doi.org/10.1136/rmdopen-2022-002321
58. Soltani-Arabshahi R, Wong B, Feng BJ, Goldgar DE, Duffin KC, Krueger GG. Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol. 2010;146(7):721-726. Available from: https://doi.org/10.1001/archdermatol.2010.141
59. Zabotti A, De Lucia O, Sakellariou G, Batticciotto A, Cincinelli G, Giovannini I, et al. Predictors, risk factors, and incidence rates of psoriatic arthritis development in psoriasis patients: a systematic literature review and meta-analysis. Rheumatol Ther. 2021;8(4):1519-1534. Available from: https://doi.org/10.1007/s40744-021-00378-w
60. Galarza-Delgado DA, Azpiri-Lopez JR, Flores-Alvarado DE, Guajardo-Jauregui N, Cardenas-de la Garza JA, Arvizu-Rivera RI, et al. Obesity is associated with higher nail psoriasis disease activity and prevalence in patients with psoriatic arthritis. Int J Dermatol. 2024;63(1):e1-e2. Available from: https://doi.org/10.1111/ijd.16933
61. Mulder MLM, Wenink MH, Vriezekolk JE. Being overweight is associated with not reaching low disease activity in women but not men with psoriatic arthritis. Rheumatology (Oxford). 2022;61(2):770-774. Available from: https://doi.org/10.1093/rheumatology/keab338
62. Upala S, Sanguankeo A. Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis. Int J Obes (Lond). 2015;39(8):1197-1202. Available from: https://doi.org/10.1038/ijo.2015.64
63. Mahil SK, McSweeney SM, Kloczko E, McGowan B, Barker JN, Smith CH. Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? A critically appraised topic. Br J Dermatol. 2019;181(5):946-953. Available from: https://doi.org/10.1111/bjd.17741
64. Poddubnyy D. Classification vs diagnostic criteria: the challenge of diagnosing axial spondyloarthritis. Rheumatology (Oxford). 2020;59(Suppl 4):iv6-iv17. Available from: https://doi.org/10.1093/rheumatology/keaa250
65. Golder V, Schachna L. Ankylosing spondylitis: an update. Aust Fam Physician. 2013;42(11):780-784. Available from: https://pubmed.ncbi.nlm.nih.gov/24217097/
66. Mathieu S, Pereira B, Soubrier M. Cardiovascular events in ankylosing spondylitis: an updated meta-analysis. Semin Arthritis Rheum. 2015;44(5):551-555. Available from: https://doi.org/10.1016/j.semarthrit.2014.10.007
67. Dean LE, Jones GT, MacDonald AG, Downham C, Sturrock RD, Macfarlane GJ. Global prevalence of ankylosing spondylitis. Rheumatology (Oxford). 2014;53(4):650-657. Available from: https://doi.org/10.1093/rheumatology/ket387
68. de Winter JJ, van Mens LJ, van der Heijde D, Landewé R, Baeten DL. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis. Arthritis Res Ther. 2016;18(1):196. Available from: https://doi.org/10.1186/s13075-016-1093-z
69. Zhao SS, Robertson S, Reich T, Harrison NL, Moots RJ, Goodson NJ. Prevalence and impact of comorbidities in axial spondyloarthritis: systematic review and meta-analysis. Rheumatology (Oxford). 2020;59(Suppl 4):iv47-iv57. Available from: https://doi.org/10.1093/rheumatology/keaa246
70. Harpsøe MC, Basit S, Andersson M, Nielsen NM, Frisch M, Wohlfahrt J, et al. Body mass index and risk of autoimmune diseases: a study within the Danish National Birth Cohort. Int J Epidemiol. 2014;43(3):843-855. Available from: https://doi.org/10.1093/ije/dyu045
71. Guanghua D, Yunjun S. Assessing the causal relationship between obesity and ankylosing spondylitis: a two-sample Mendelian randomization study. Medicine (Baltimore). 2025;104(21):e42559. Available from: https://doi.org/10.1097/MD.0000000000042559
72. Ortolan A, Lorenzin M, Felicetti M, Ramonda R. Do obesity and overweight influence disease activity measures in axial spondyloarthritis? A systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2021;73(12):1815-1825. Available from: https://doi.org/10.1002/acr.24416
73. Liew JW, Huang IJ, Louden DN, Singh N, Gensler LS. Association of body mass index on disease activity in axial spondyloarthritis: systematic review and meta-analysis. RMD Open. 2020;6(1):e001225. Available from: https://doi.org/10.1136/rmdopen-2020-001225
74. Chen CH, Chen HA, Liu CH, Liao HT, Chou CT, Chen CH. Association of obesity with inflammation, disease severity and cardiovascular risk factors among patients with ankylosing spondylitis. Int J Rheum Dis. 2020;23(9):1165-1174. Available from: https://doi.org/10.1111/1756-185X.13912
75. Kim SK, Choe JY, Lee SS, Shin K. Body mass index is related with the presence of syndesmophyte in axial spondyloarthritis: data from the KOBIO registry. Mod Rheumatol. 2017;27(5):855-861. Available from: https://doi.org/10.1080/14397595.2016.1265637
76. Jones GT, Rotariu O, MacDonald R, Michelsen B, Glintborg B, van der Horst-Bruinsma I, et al. The relationship between lifestyle factors and outcome of treatment with TNFα inhibitors in axial spondyloarthritis - results from 14 European countries. BMC Rheumatol. 2025;9(1):88. Available from: https://doi.org/10.1186/s41927-025-00529-4
77. Hernández-Breijo B, Plasencia-Rodríguez C, Navarro-Compán V, Martínez-Feito A, Jochems A, Kneepkens EL, et al. Association between concomitant csDMARDs and clinical response to TNF inhibitors in overweight patients with axial spondyloarthritis. Arthritis Res Ther. 2019;21(1):66. Available from: https://doi.org/10.1186/s13075-019-1849-3
78. van der Heijde D, Baraliakos X, Sieper J, Deodhar A, Inman RD, Kameda H, et al. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial. Ann Rheum Dis. 2022;81(11):1515-1523. Available from: https://doi.org/10.1136/ard-2022-222608
79. Karakaş A, Gulle S, Can G, Dalkılıc E, Akar S, Koca SS, et al. Does obesity affect treatment response to secukinumab and survival in ankylosing spondylitis? Real-life data from the TURKBIO Registry. Mod Rheumatol. 2024;34(3):584-591. Available from: https://doi.org/10.1093/mr/road061
80. Dubreuil M, Navarro-Compán V, Boonen A, Gaffney K, Gensler LS, de la Loge C, et al. Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies. RMD Open. 2024;10(2):e004202. Available from: https://doi.org/10.1136/rmdopen-2024-004202
81. Rossato, S., Oakes, E. G., Barbhaiya, M., Sparks, J. A., Malspeis, S., Willett, W. C., Khandpur, N., & Costenbader, K. H. (2025). Ultraprocessed Food Intake and Risk of Systemic Lupus Erythematosus Among Women Observed in the Nurses' Health Study Cohorts. Arthritis care & research, 77(1), 50–60. Available from: https://doi.org/10.1002/acr.25395
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Mateusz Pysiewicz, Olga Stadnicka, Anna Knapik, Anna Brodowska, Justyna Kuś, Patrycja Białowąs, Natalia Zięba, Olgierd Czapiński, Ewa Tomicka, Maciej Ciesielski
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 69
Number of citations: 0
